Effects of transdermal estrogen on levels of lipids, lipase activity, and inflammatory markers in men with prostate cancer

Jonathan Purnell, Lisa B. Bland, Mark Garzotto, Dianne Lemmon, Emily M. Wersinger, Christopher Ryan, John D. Brunzell, Tomasz (Tom) Beer

Research output: Contribution to journalArticle

19 Citations (Scopus)

Abstract

Androgen deprivation therapy (ADT) for prostate cancer is now used in earlier disease stages and as adjuvant treatment. Recognizing and reducing the toxicity of this therapy, including worsened lipid levels and cardiovascular disease (CVD) risks, has become an important clinical concern. Oral estrogen therapy induces hypogonadism and mitigates many side effects of ADT, but has a high thrombosis risk. Transdermal estrogen therapy (TDE) has a lower thrombosis risk than oral estrogen and may improve CVD risk compared with ADT. This prospective pilot study of 18 men with androgen-independent prostate cancer receiving ADT measured effects of TDE on lipid and inflammatory CVD risk factors before and after 8 weeks of TDE (estradiol 0.6 mg/day). During treatment, estradiol levels rose 17-fold; total cholesterol, LDL cholesterol, and apolipoprotein B levels decreased. HDL2 cholesterol increased, with no changes in triglyceride or VLDL cholesterol levels. Dense LDL cholesterol decreased and LDL buoyancy increased in association with a decrease in HL activity. Highly sensitive C-reactive protein levels and other inflammatory markers did not worsen.jlr Compared with ADT, short-term TDE therapy of prostate cancer improves lipid levels without deterioration of CVD-associated inflammatory markers and may, on longer-term follow-up, improve CVD and mortality rates.

Original languageEnglish (US)
Pages (from-to)349-355
Number of pages7
JournalJournal of Lipid Research
Volume47
Issue number2
DOIs
StatePublished - Feb 2006

Fingerprint

Lipase
Androgens
Prostatic Neoplasms
Estrogens
Lipids
LDL Cholesterol
Cardiovascular Diseases
Estradiol
Therapeutics
VLDL Cholesterol
Cholesterol
Apolipoproteins B
Buoyancy
C-Reactive Protein
HDL Cholesterol
Toxicity
Deterioration
Triglycerides
Thrombosis
Hypogonadism

Keywords

  • Androgen deprivation therapy
  • Apolipoprotein
  • Estradiol
  • Inflammation

ASJC Scopus subject areas

  • Endocrinology

Cite this

Effects of transdermal estrogen on levels of lipids, lipase activity, and inflammatory markers in men with prostate cancer. / Purnell, Jonathan; Bland, Lisa B.; Garzotto, Mark; Lemmon, Dianne; Wersinger, Emily M.; Ryan, Christopher; Brunzell, John D.; Beer, Tomasz (Tom).

In: Journal of Lipid Research, Vol. 47, No. 2, 02.2006, p. 349-355.

Research output: Contribution to journalArticle

@article{5da666a560474803b0e769013035aa3a,
title = "Effects of transdermal estrogen on levels of lipids, lipase activity, and inflammatory markers in men with prostate cancer",
abstract = "Androgen deprivation therapy (ADT) for prostate cancer is now used in earlier disease stages and as adjuvant treatment. Recognizing and reducing the toxicity of this therapy, including worsened lipid levels and cardiovascular disease (CVD) risks, has become an important clinical concern. Oral estrogen therapy induces hypogonadism and mitigates many side effects of ADT, but has a high thrombosis risk. Transdermal estrogen therapy (TDE) has a lower thrombosis risk than oral estrogen and may improve CVD risk compared with ADT. This prospective pilot study of 18 men with androgen-independent prostate cancer receiving ADT measured effects of TDE on lipid and inflammatory CVD risk factors before and after 8 weeks of TDE (estradiol 0.6 mg/day). During treatment, estradiol levels rose 17-fold; total cholesterol, LDL cholesterol, and apolipoprotein B levels decreased. HDL2 cholesterol increased, with no changes in triglyceride or VLDL cholesterol levels. Dense LDL cholesterol decreased and LDL buoyancy increased in association with a decrease in HL activity. Highly sensitive C-reactive protein levels and other inflammatory markers did not worsen.jlr Compared with ADT, short-term TDE therapy of prostate cancer improves lipid levels without deterioration of CVD-associated inflammatory markers and may, on longer-term follow-up, improve CVD and mortality rates.",
keywords = "Androgen deprivation therapy, Apolipoprotein, Estradiol, Inflammation",
author = "Jonathan Purnell and Bland, {Lisa B.} and Mark Garzotto and Dianne Lemmon and Wersinger, {Emily M.} and Christopher Ryan and Brunzell, {John D.} and Beer, {Tomasz (Tom)}",
year = "2006",
month = "2",
doi = "10.1194/jlr.M500276-JLR200",
language = "English (US)",
volume = "47",
pages = "349--355",
journal = "Journal of Lipid Research",
issn = "0022-2275",
publisher = "American Society for Biochemistry and Molecular Biology Inc.",
number = "2",

}

TY - JOUR

T1 - Effects of transdermal estrogen on levels of lipids, lipase activity, and inflammatory markers in men with prostate cancer

AU - Purnell, Jonathan

AU - Bland, Lisa B.

AU - Garzotto, Mark

AU - Lemmon, Dianne

AU - Wersinger, Emily M.

AU - Ryan, Christopher

AU - Brunzell, John D.

AU - Beer, Tomasz (Tom)

PY - 2006/2

Y1 - 2006/2

N2 - Androgen deprivation therapy (ADT) for prostate cancer is now used in earlier disease stages and as adjuvant treatment. Recognizing and reducing the toxicity of this therapy, including worsened lipid levels and cardiovascular disease (CVD) risks, has become an important clinical concern. Oral estrogen therapy induces hypogonadism and mitigates many side effects of ADT, but has a high thrombosis risk. Transdermal estrogen therapy (TDE) has a lower thrombosis risk than oral estrogen and may improve CVD risk compared with ADT. This prospective pilot study of 18 men with androgen-independent prostate cancer receiving ADT measured effects of TDE on lipid and inflammatory CVD risk factors before and after 8 weeks of TDE (estradiol 0.6 mg/day). During treatment, estradiol levels rose 17-fold; total cholesterol, LDL cholesterol, and apolipoprotein B levels decreased. HDL2 cholesterol increased, with no changes in triglyceride or VLDL cholesterol levels. Dense LDL cholesterol decreased and LDL buoyancy increased in association with a decrease in HL activity. Highly sensitive C-reactive protein levels and other inflammatory markers did not worsen.jlr Compared with ADT, short-term TDE therapy of prostate cancer improves lipid levels without deterioration of CVD-associated inflammatory markers and may, on longer-term follow-up, improve CVD and mortality rates.

AB - Androgen deprivation therapy (ADT) for prostate cancer is now used in earlier disease stages and as adjuvant treatment. Recognizing and reducing the toxicity of this therapy, including worsened lipid levels and cardiovascular disease (CVD) risks, has become an important clinical concern. Oral estrogen therapy induces hypogonadism and mitigates many side effects of ADT, but has a high thrombosis risk. Transdermal estrogen therapy (TDE) has a lower thrombosis risk than oral estrogen and may improve CVD risk compared with ADT. This prospective pilot study of 18 men with androgen-independent prostate cancer receiving ADT measured effects of TDE on lipid and inflammatory CVD risk factors before and after 8 weeks of TDE (estradiol 0.6 mg/day). During treatment, estradiol levels rose 17-fold; total cholesterol, LDL cholesterol, and apolipoprotein B levels decreased. HDL2 cholesterol increased, with no changes in triglyceride or VLDL cholesterol levels. Dense LDL cholesterol decreased and LDL buoyancy increased in association with a decrease in HL activity. Highly sensitive C-reactive protein levels and other inflammatory markers did not worsen.jlr Compared with ADT, short-term TDE therapy of prostate cancer improves lipid levels without deterioration of CVD-associated inflammatory markers and may, on longer-term follow-up, improve CVD and mortality rates.

KW - Androgen deprivation therapy

KW - Apolipoprotein

KW - Estradiol

KW - Inflammation

UR - http://www.scopus.com/inward/record.url?scp=33244469248&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=33244469248&partnerID=8YFLogxK

U2 - 10.1194/jlr.M500276-JLR200

DO - 10.1194/jlr.M500276-JLR200

M3 - Article

C2 - 16299398

AN - SCOPUS:33244469248

VL - 47

SP - 349

EP - 355

JO - Journal of Lipid Research

JF - Journal of Lipid Research

SN - 0022-2275

IS - 2

ER -